Clinical Trial Update: AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites [Phase 2]

View source ↗

Summary

Phase 2 trial of AVE0005 (VEGF Trap) in patients with recurrent symptomatic malignant ascites due to ovarian neoplasms; results were posted in January 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• AVE0005 (VEGF Trap) (ziv-aflibercept)

Snippet

Sponsor: Sanofi | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2013-01-10